Back to Agenda
Session 13: Drug Master Files
Session Chair(s)
Albert S. Yehaskel, MBA
President and CEO
Refuah Global Pharmaceutical Development, Inc., United States
- Regulatory Basis
- DMF Submissions
- Transmittal Letter
- Administrative Information
- FDA Review of DMFs
- Types I, II, III, IV, and V DMFs
- General Suggestions
- Letters of Authorization
- Holder Obligations
- Transfer of Ownership and Potential Issues
Have an account?